Croatia Joins European Medicines Network - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Croatia Joins European Medicines Network


Croatia joined the European Union on July 1, 2013 and, therefore, became part of the European Medicines Network. The country will now be involved in European Medicines Agency (EMA) activities. Europe began preparing for Croatia’s participation in 2007 with the creation of the Instrument for Pre-accession Assistance (IPA) program and with ongoing work with Croatian authorities. Croatia participated in selected EMA meetings as part of the IPA program.

EMA and Croatia also started a pre-accession linguistic review of product information in January 2011 to facilitate “the phasing-in of European Commission decisions on centrally authorised medicines once Croatia joined the EU thereby avoiding delays in the supply of medicines in Croatia.” EMA has issued revised guidance that outlines the phasing-in of authorized products in Croatia and operational aspects. 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here